PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022
July 27, 2022 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting
July 25, 2022 07:00 ET
|
PolyPid Ltd.
Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation PETACH TIKVA, Israel, July 25,...
PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO
July 05, 2022 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, July 05, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today...
PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections
June 15, 2022 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022
June 06, 2022 07:00 ET
|
PolyPid Ltd.
Phase 2 clinical data on the efficacy of D-PLEX100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation PETACH TIKVA, Israel, June 06,...
PolyPid to Present at the JMP Securities 2022 Life Sciences Conference
June 02, 2022 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects
June 01, 2022 07:00 ET
|
PolyPid Ltd.
Locally Administered Docetaxel Through Extended-Release Delivery via the Company’s PLEX Technology Offers Potentially Enhanced Adjuvant Chemotherapy Option PETACH TIKVA, Israel, June 01, 2022 ...
PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery
May 31, 2022 07:00 ET
|
PolyPid Ltd.
Following Unblinded Interim Efficacy Analysis, Data Safety Monitoring Board Recently Recommended Concluding Study at 950 Patients, the Minimum Number of Patients TargetedTop-line Results Expected by...
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis
May 23, 2022 07:00 ET
|
PolyPid Ltd.
• Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days • Top-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions...
PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 11, 2022 07:00 ET
|
PolyPid Ltd.
• Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently • Recruitment Progressing as Planned with Approximately 900...